1. Pink Sheet
  2. >>Geography
  3. >>Europe

Europe Stands Firm On Nitrosamine Assessment Deadline For APIs

Companies Can Suggest New Timeline In Justified Cases

 
• By Vibha Sharma

The European Directorate for the Quality of Medicines & HealthCare says it will not extend the deadline for nitrosamine-related risk assessment of active substances even though an extension is in place for assessments of finished products.

woman in a laboratory microscope with microscope slide in hand.toned image.
Nitrosamine impurities have been found in marketed medicines in the recent past • Source: Shutterstock

Companies that missed the 31 July deadline to evaluate their chemically synthesized active pharmaceutical ingredients (APIs) to identify those at risk of nitrosamine contamination are being advised to contact the European Directorate for the Quality of Medicines & HealthCare (EDQM) with a new justifiable timeline.

On 17 August, the EDQM said it would not grant any more extensions for such risk evaluations for APIs,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Report Shows Extent Of AI Use In EU Medicines Regulation During 2024

 
• By Eliza Slawther

The AI observatory, created by the European medicines regulatory network to track the evolving use of artificial intelligence in medicines development and regulation, has issued its first annual report.

Prasad Cites Unproven Theory Defending His COVID-19 Vaccine Decisions

 
• By Sarah Karlin-Smith

In defending his decision to overrule agency staff on three recent COVID-19 vaccine applications, the CBER director questioned the original timing of Pfizer’s COVID-19 vaccine authorization, reviving a long-held, but unproven grievance of President Trump.

33 States Agree To Standardized Access Policies In Medicaid Sickle Cell Payment Demo

 
• By Alaric DeArment and Cathy Kelly

States also agreed to fund patient travel to specialized treatment centers as part of their participation in the Medicaid demo of CMS-negotiated outcomes-based contracts for Vertex/CRISPR's Casgevy and bluebird bio's Lyfgenia.